Pfizer-BioNTech COVID-19 vaccine information

This page contains documents relating specifically to the Pfizer BioNTech COVID-19 and Comirnaty® vaccine.

National protocol for Comirnaty® COVID-19 mRNA vaccine

National protocol for Comirnaty® 10 microgram/dose COVID-19 mRNA vaccine

National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech) (withdrawn on 20 April 2022)

 

Pfizer BioNTech COVID-19 vaccine information

Gov.uk - Regulatory approval of COVID-19 Pfizer BioNTech vaccine	Regulatory approval of COVID-19 Pfizer BioNTech vaccine
Comirnaty® vaccine Patient Information Leaflet	COVID-19: vaccine Comirnaty® Patient Information Leaflet COVID-19: vaccine Comirnaty® (10micrograms/dose) concentrate Patient Information Leaflet Children 5 to 11
Comirnaty® vaccine SPC	COVID-19: vaccine Comirnaty® 'SPC' COVID-19: vaccine Comirnaty® (10micrograms/dose) concentrate 'SPC' Children 5 to 11
Pfizer BioNTech vaccine SPC	COVID-19: vaccine BNT162b2 'SPC'
Patient Group Direction for Comirnaty®	Patient Group Direction for Comirnaty® (Pfizer BioNTech) Patient Group Direction for Comirnaty® (10micrograms/dose) concentrate for children 5-11 years
Patient Specific Direction Pfizer vaccine (for local adoption)	Individual Patient assessment to assist the creation of Patient Specific Direction for the administration of the Pfizer vaccine
Pfizer BioNTech vaccine Patient Information Leaflet	COVID-19: vaccine BNT162b2 Patient Information Leaflet
Pfizer Vaccine Ingredients	Pfizer Vaccine Ingredients
British Islamic Medical Association statement	British Islamic Medical Association: Position statement on the Pfizer/BioNTech COVID-19 vaccine

 

SPS Pfizer-BioNTech information

Information specific to Pfizer-BioNTech vaccine

Managing risks associated with the introduction of the Comirnaty vaccine for children 5 to 11 years old